Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Kei Kishimoto"'
Autor:
Earl Sands, Alan Kivitz, Wesley DeHaan, Sheldon S. Leung, Lloyd Johnston, Takashi Kei Kishimoto
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-7 (2022)
Anti-drug antibodies (ADA) induced by biologic drugs may hamper the efficacy of treatment, so inhibiting ADA induction is desirable. Here, in two clinical trials, the authors show that ImmTOR, previously reported to reduce drug immunogenicity in anim
Externí odkaz:
https://doaj.org/article/de97b0524c024b9b8277b1e7a9bd7ca8
Autor:
Petr O. Ilyinskii, Alicia M. Michaud, Gina L. Rizzo, Christopher J. Roy, Sheldon S. Leung, Stephanie L. Elkins, Teresa Capela, Aparajita Chowdhury, Lina Li, Randy J. Chandler, Irini Manoli, Eva Andres-Mateos, Lloyd P.M. Johnston, Luk H. Vandenberghe, Charles P. Venditti, Takashi Kei Kishimoto
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 279-292 (2021)
A major barrier to adeno-associated virus (AAV) gene therapy is the inability to re-dose patients due to formation of vector-induced neutralizing antibodies (Nabs). Tolerogenic nanoparticles encapsulating rapamycin (ImmTOR) provide long-term and spec
Externí odkaz:
https://doaj.org/article/6698961584084f2e8ca2b818f89110a5
Autor:
Giulia De Sabbata, Florence Boisgerault, Corrado Guarnaccia, Alessandra Iaconcig, Giulia Bortolussi, Fanny Collaud, Giuseppe Ronzitti, Marcelo Simon Sola, Patrice Vidal, Jeremy Rouillon, Severine Charles, Emanuele Nicastro, Lorenzo D’Antiga, Petr Ilyinskii, Federico Mingozzi, Takashi Kei Kishimoto, Andrés F. Muro
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss , Pp 169-180 (2021)
Ornithine transcarbamylase deficiency (OTCD) is an X-linked liver disorder caused by partial or total loss of OTC enzyme activity. It is characterized by elevated plasma ammonia, leading to neurological impairments, coma, and death in the most severe
Externí odkaz:
https://doaj.org/article/3a96d0d695e64c20a8383d4f8962ab9a
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
ImmTOR biodegradable nanoparticles encapsulating rapamycin have been shown to induce a durable tolerogenic immune response to co-administered biologics and gene therapy vectors. Prior mechanism of action studies have demonstrated selective biodistrib
Externí odkaz:
https://doaj.org/article/0f2b772449e14d9f99138800a8a3b1f1
Autor:
Takashi Kei Kishimoto
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The development of anti-drug antibodies (ADAs) is a common cause for treatment failure and hypersensitivity reactions for many biologics. The focus of this review is the development of ImmTOR, a platform technology designed to prevent the formation o
Externí odkaz:
https://doaj.org/article/37a5d20e5e204f1d8eef7f09c6d791e9
Autor:
Amine Meliani, Florence Boisgerault, Romain Hardet, Solenne Marmier, Fanny Collaud, Giuseppe Ronzitti, Christian Leborgne, Helena Costa Verdera, Marcelo Simon Sola, Severine Charles, Alban Vignaud, Laetitia van Wittenberghe, Giorgia Manni, Olivier Christophe, Francesca Fallarino, Christopher Roy, Alicia Michaud, Petr Ilyinskii, Takashi Kei Kishimoto, Federico Mingozzi
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Immunogenicity of AAV vectors renders repeated AAV dosing ineffective. Here the authors show that coadministration of nanoparticle-encapsulated rapamycin overcomes AAV immunogenicity through Treg induction, enabling efficient AAV redosing in mice and
Externí odkaz:
https://doaj.org/article/8c201057906f4f2d8d990ffb8e12cbae
Autor:
Takashi Kei Kishimoto, Max Fournier, Alicia Michaud, Gina Rizzo, Christopher Roy, Teresa Capela, Natasha Nukolova, Ning Li, Liam Doyle, Fen-ni Fu, Derek VanDyke, Peter G. Traber, Jamie B. Spangler, Sheldon S. Leung, Petr O. Ilyinskii
Low dose IL-2 therapy and IL-2 molecules engineered to be selective for the high affinity IL-2 receptor have been shown to expand Tregs in vivo, and, in the case of low dose IL-2 therapy, has demonstrated promising therapeutic benefit in autoimmune d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be2d4887a24da1329f57ba27cffe21e8
https://doi.org/10.1101/2023.05.15.540840
https://doi.org/10.1101/2023.05.15.540840
Publikováno v:
Expert Opinion on Biological Therapy. 22:1067-1071
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030f45c9841e39d4c15f3ef4ae37cdce
https://doi.org/10.1080/14712598.2022.2060737
https://doi.org/10.1080/14712598.2022.2060737
Autor:
Haruko Hayasaka, Junichi Yoshida, Yasutaka Kuroda, Akihiro Nishiguchi, Michiya Matsusaki, Kei Kishimoto, Hitoshi Nishimura, Mari Okada, Yuki Shimomura, Daichi Kobayashi, Yoshihito Shimazu, Yuji Taya, Mitsuru Akashi, Masayuki Miyasaka
Publikováno v:
Cancer Science. 113:1338-1351
Chemokines are a family of cytokines that mediate leukocyte trafficking and are involved in tumor cell migration, growth, and progression. Although there is emerging evidence that multiple chemokines are expressed in tumor tissues and that each chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29be3e66d9991b6a913325475a3167b1
https://doi.org/10.1111/cas.15293
https://doi.org/10.1111/cas.15293
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Antigen-specific immune tolerance has been a long-standing goal for immunotherapy for the treatment of autoimmune diseases and allergies and for the prevention of allograft rejection and anti-drug antibodies directed against biologic therapies. Nanop
Externí odkaz:
https://doaj.org/article/a6cdae453ead4af5abee446e8d9b09f2